Immunocompromised Patients
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
RNA Therapeutic
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
1 programNoninvasive mechanical ventilationN/A1 trial
Active Trials
ModernaCAMBRIDGE, MA
1 programModerna COVID-19 Vaccine, mRNA-1273PHASE_3RNA Therapeutic1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
ModernaModerna COVID-19 Vaccine, mRNA-1273
UNION therapeuticsNoninvasive mechanical ventilation
Clinical Trials (2)
Total enrollment: 848 patients across 2 trials
Immunocompromised Swiss Cohorts Based Trial Platform
Start: Apr 2021Est. completion: Sep 2023610 patients
Phase 3Completed
Initial Ventilation Strategy for Adult Immunocompromised Patients With Acute Respiratory Failure
Start: Dec 2016Est. completion: Dec 2018238 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.